Aurisco Pharmaceutical Co. Ltd. Class A 605116

SSE · China · Health Technology

CNY 20.07+0.79 (+4.10%)

Market closed· Sep 30, 2026, 7:00 AM UTC· CNY · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

Aurisco Pharmaceutical Co. Ltd. Class A 605116

SSE · China · Health Technology

CNY 20.07+0.79 (+4.10%)

Market closed· Sep 30, 2026, 7:00 AM UTC· CNY · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

-24.89% · 6MFull-screen chart

Open CNY 19.20High CNY 20.22Low CNY 19.20Close CNY 20.07Volume 3.74M

Sep 30, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: CNY 19.28
Day range: CNY 19.20 – CNY 20.22
52-week range: CNY 18.09 – CNY 35.58
Volume: 3.74M
Market cap: CNY 8.15B
P/E (TTM): 22.1
Dividend yield (annualized): 1.69%
Next earnings date: 2026-10-31
Avg. volume (1Y): 4.11M

Performance

1 week

+0.55%

1 month

+0.96%

3 months

-0.64%

6 months

-28.45%

Year to date

-21.55%

1 year

-9.00%

Total return, dividends included.

Company profile

Sector: Health Technology
Industry: Pharmaceuticals: Major
Country: China
Exchange: SSE
Shares outstanding: 403.44M
Employees: 2,026
ISIN: CNE1000042S4
Beta: 0.21

Technical view

Mixed

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceAug 12, 2026

Aurisco Pharmaceutical is the First Generic Oligonucleotide Manufacturer in the World successfully inspected by USFDA

Aurisco Pharmaceutical, a leading global Oligonucleotide and Peptide (TIDES) manufacturer, announced today that its site in Yangzhou, China has passed the USFDA inspection as the first generic Oligonucleotide API manufacturer in the world.

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.